Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
It is developing the drug candidate to potentially treat immunological diseases
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Subscribe To Our Newsletter & Stay Updated
